Figure 8. MAPK-ERK1/2 signaling is activated by high ROS in NT2 cells.

(A) Cells were treated with the increasing concentrations of paraquat (PQ). The activation status of ERK1/2 and the upstream MEK1/2 was determined by immunoblotting with indicated antibodies. β-ACTIN was used as the loading control. (B) Cells were treated with indicated doses of MEK1/2 inhibitor, SL327. The efficacy of the inhibitor was demonstrated by immunoblotting for phospho-ERK1/2. (C) Cells were concurrently treated with 100 μM paraquat and indicated doses of SL327 for 6 days. The phase contrast images showed the cell density and morphology under different treatments. Scale bar: 100 µm.